Concept and Practice of Therapeutic Teams
Proceedings of the 11th European Symposium on Clinical Pharmacy, Brussels 1982
Herausgeber: De Clercq, H.; Bonal, Joaquin; Poston, J. W.
Concept and Practice of Therapeutic Teams
Proceedings of the 11th European Symposium on Clinical Pharmacy, Brussels 1982
Herausgeber: De Clercq, H.; Bonal, Joaquin; Poston, J. W.
- Broschiertes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
This 1983 book reports the proceedings of the eleventh European symposium on clinical pharmacy which was held in Brussels in October 1982.
Andere Kunden interessierten sich auch für
- Joe Correa54 Post Chemotherapy Juice Recipes22,99 €
- Aimee MichaelsI Rocked Cancer To The Core17,99 €
- Thomas GruberNavigating Glioblastoma and High-Grade Glioma14,99 €
- Aimee MichaelsThe Chemo Made Me Do It17,99 €
- Paul MacleanA Triune Concept of the Brain and Behaviour35,99 €
- National Cancer InstitutionA Handbook for Clinical Investigators Conducting Therapeutic Clinical Trials Supported by CTEP, DCTD, NCI33,99 €
- Mukesh Kumar SharmaTherapeutic Implications of Natural Bioactive Compounds91,99 €
-
-
-
This 1983 book reports the proceedings of the eleventh European symposium on clinical pharmacy which was held in Brussels in October 1982.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: Cambridge University Press
- Seitenzahl: 266
- Erscheinungstermin: 11. Februar 2011
- Englisch
- Abmessung: 229mm x 152mm x 16mm
- Gewicht: 437g
- ISBN-13: 9780521279178
- ISBN-10: 0521279178
- Artikelnr.: 33611989
- Herstellerkennzeichnung
- Libri GmbH
- Europaallee 1
- 36244 Bad Hersfeld
- gpsr@libri.de
- Verlag: Cambridge University Press
- Seitenzahl: 266
- Erscheinungstermin: 11. Februar 2011
- Englisch
- Abmessung: 229mm x 152mm x 16mm
- Gewicht: 437g
- ISBN-13: 9780521279178
- ISBN-10: 0521279178
- Artikelnr.: 33611989
- Herstellerkennzeichnung
- Libri GmbH
- Europaallee 1
- 36244 Bad Hersfeld
- gpsr@libri.de
Preface; Part I. Introduction: 1. Introductory remarks; Part II. The
Concept of the Theraputic Team: 2. The concept of the therapeutic team; 3.
The view of a pharmacist; 4. The view of a physician; 5. The view of a
nurse; 6. The view of the clinical pharmacologist; 7. The view of an
academic; Part III. Practice of the Therapeutic Team: Parenteral Nutrition:
8. Parenteral nutrition - the team approach in a general hospital; 9.
Long-term follow-up in total parenteral nutrition; 10. Total parenteral
nutrition of children at the State University Hospital of Copenhagen; 11.
Compatibility of two different fat emulsions with amino-acids, carbohydrate
and electrolytes in parenteral nutrition mixtures; 12. Esophagus cancer and
parenteral nutrition: postoperative complications and P. N. I.
relationship. Preliminary study; Part IV. Oncology: 13. Central nervous
system prohylaxis of acute lymphoblastic leukemia with methotrexate; 14.
The treatment protocols of acute lymphoblastic leukemia in children; 15.
Guidelines for the safe handling of minibags; 16. Centralization of
preparation of cytotoxic drugs in the central pharmacy: one year of
experience; 17. Progress in the management of high dose methotrexate; 18.
Parmacokinetics of cytosine arabinoside in leukemic patients with normal
and impaired hepatic functions, preliminary results; PartV. Dermatology:
19. The operation of a therapeutic team in dermatology; Part VI. Epilepsy:
20. Team treatment of epilepsy; 21. Practices of the therapeutic team in
epilepsy; 22. Interdisciplinary approach to the treatment of epilepsy; 23.
The role of clinical pharmacist in the monitoring of antiepileptic therapy
in clinics with ambulant patients, our experience with 45 patients; Part
VII. Internal Medicine - Rheumatology: 24. An approach to the therapeutic
strategy in rheumatoid arthritis. Adverse reactions to penicillamine-like
drugs used in the treatment of rheumatoid arthritis; Part VIII. Nuclear
Medicine: 25. The nuclear medicine team; 26. Practice of the nuclear
medicine therapeutic team: the role of the physician; 27. Practice of the
nuclear medicine therapeutic team: the role of the physicist; 28. Practice
of the nuclear medicine therapeutic team: the role of the radiotherapist;
Part IX. Drug Selection: 29. Collaboration in drug selection - preparing
the London Hospital Formulary 1982 - guide to the prescribing of medicines:
introduction; 30. A clinician's view on the team approach to drug
selection; 31. A pharmacists view on the team approach to drug selection;
32. Conclusion; 33. Restrictive formulary management with consequences for
the treatment of individual patients; 34. Changes in patterns of analgesic
use; Part X. Pharmacokinetics, Dialysis, I. V. Therapy: 35. Clinical
pharmacy improvement and interrelation with therapeutci team; 36. Clinical
pharmacist participation in a clinical trial - treatment of congestive
heart failure; 37. Metronidazole plasma levels after I. V. and rectal
administration; 38. Individual factors influencing aminoglycoside serum
levels; 39. Monitoring theophylline plasma levels; 40. Comparison of four
pharmacokinetic methods for individualizing phenytoin dosage; 41. Use of a
calculator program for individualized estimation of pheyoin kinetic
parameters by a least-squares technique; 42. On the importance of regular
Al determination in patients on regular hemodialysis (RHD); 43. Manufacture
of dialysis concentrate at the level of a hospital; 44. Hospital
preparation of injectable drugs by means of a multi-additive pump; 45. How
to detect physico-chemical incompatabilities in I. V. admixtures; 46.
Preparation of an enema containing metaminosalicylic acid
Concept of the Theraputic Team: 2. The concept of the therapeutic team; 3.
The view of a pharmacist; 4. The view of a physician; 5. The view of a
nurse; 6. The view of the clinical pharmacologist; 7. The view of an
academic; Part III. Practice of the Therapeutic Team: Parenteral Nutrition:
8. Parenteral nutrition - the team approach in a general hospital; 9.
Long-term follow-up in total parenteral nutrition; 10. Total parenteral
nutrition of children at the State University Hospital of Copenhagen; 11.
Compatibility of two different fat emulsions with amino-acids, carbohydrate
and electrolytes in parenteral nutrition mixtures; 12. Esophagus cancer and
parenteral nutrition: postoperative complications and P. N. I.
relationship. Preliminary study; Part IV. Oncology: 13. Central nervous
system prohylaxis of acute lymphoblastic leukemia with methotrexate; 14.
The treatment protocols of acute lymphoblastic leukemia in children; 15.
Guidelines for the safe handling of minibags; 16. Centralization of
preparation of cytotoxic drugs in the central pharmacy: one year of
experience; 17. Progress in the management of high dose methotrexate; 18.
Parmacokinetics of cytosine arabinoside in leukemic patients with normal
and impaired hepatic functions, preliminary results; PartV. Dermatology:
19. The operation of a therapeutic team in dermatology; Part VI. Epilepsy:
20. Team treatment of epilepsy; 21. Practices of the therapeutic team in
epilepsy; 22. Interdisciplinary approach to the treatment of epilepsy; 23.
The role of clinical pharmacist in the monitoring of antiepileptic therapy
in clinics with ambulant patients, our experience with 45 patients; Part
VII. Internal Medicine - Rheumatology: 24. An approach to the therapeutic
strategy in rheumatoid arthritis. Adverse reactions to penicillamine-like
drugs used in the treatment of rheumatoid arthritis; Part VIII. Nuclear
Medicine: 25. The nuclear medicine team; 26. Practice of the nuclear
medicine therapeutic team: the role of the physician; 27. Practice of the
nuclear medicine therapeutic team: the role of the physicist; 28. Practice
of the nuclear medicine therapeutic team: the role of the radiotherapist;
Part IX. Drug Selection: 29. Collaboration in drug selection - preparing
the London Hospital Formulary 1982 - guide to the prescribing of medicines:
introduction; 30. A clinician's view on the team approach to drug
selection; 31. A pharmacists view on the team approach to drug selection;
32. Conclusion; 33. Restrictive formulary management with consequences for
the treatment of individual patients; 34. Changes in patterns of analgesic
use; Part X. Pharmacokinetics, Dialysis, I. V. Therapy: 35. Clinical
pharmacy improvement and interrelation with therapeutci team; 36. Clinical
pharmacist participation in a clinical trial - treatment of congestive
heart failure; 37. Metronidazole plasma levels after I. V. and rectal
administration; 38. Individual factors influencing aminoglycoside serum
levels; 39. Monitoring theophylline plasma levels; 40. Comparison of four
pharmacokinetic methods for individualizing phenytoin dosage; 41. Use of a
calculator program for individualized estimation of pheyoin kinetic
parameters by a least-squares technique; 42. On the importance of regular
Al determination in patients on regular hemodialysis (RHD); 43. Manufacture
of dialysis concentrate at the level of a hospital; 44. Hospital
preparation of injectable drugs by means of a multi-additive pump; 45. How
to detect physico-chemical incompatabilities in I. V. admixtures; 46.
Preparation of an enema containing metaminosalicylic acid
Preface; Part I. Introduction: 1. Introductory remarks; Part II. The
Concept of the Theraputic Team: 2. The concept of the therapeutic team; 3.
The view of a pharmacist; 4. The view of a physician; 5. The view of a
nurse; 6. The view of the clinical pharmacologist; 7. The view of an
academic; Part III. Practice of the Therapeutic Team: Parenteral Nutrition:
8. Parenteral nutrition - the team approach in a general hospital; 9.
Long-term follow-up in total parenteral nutrition; 10. Total parenteral
nutrition of children at the State University Hospital of Copenhagen; 11.
Compatibility of two different fat emulsions with amino-acids, carbohydrate
and electrolytes in parenteral nutrition mixtures; 12. Esophagus cancer and
parenteral nutrition: postoperative complications and P. N. I.
relationship. Preliminary study; Part IV. Oncology: 13. Central nervous
system prohylaxis of acute lymphoblastic leukemia with methotrexate; 14.
The treatment protocols of acute lymphoblastic leukemia in children; 15.
Guidelines for the safe handling of minibags; 16. Centralization of
preparation of cytotoxic drugs in the central pharmacy: one year of
experience; 17. Progress in the management of high dose methotrexate; 18.
Parmacokinetics of cytosine arabinoside in leukemic patients with normal
and impaired hepatic functions, preliminary results; PartV. Dermatology:
19. The operation of a therapeutic team in dermatology; Part VI. Epilepsy:
20. Team treatment of epilepsy; 21. Practices of the therapeutic team in
epilepsy; 22. Interdisciplinary approach to the treatment of epilepsy; 23.
The role of clinical pharmacist in the monitoring of antiepileptic therapy
in clinics with ambulant patients, our experience with 45 patients; Part
VII. Internal Medicine - Rheumatology: 24. An approach to the therapeutic
strategy in rheumatoid arthritis. Adverse reactions to penicillamine-like
drugs used in the treatment of rheumatoid arthritis; Part VIII. Nuclear
Medicine: 25. The nuclear medicine team; 26. Practice of the nuclear
medicine therapeutic team: the role of the physician; 27. Practice of the
nuclear medicine therapeutic team: the role of the physicist; 28. Practice
of the nuclear medicine therapeutic team: the role of the radiotherapist;
Part IX. Drug Selection: 29. Collaboration in drug selection - preparing
the London Hospital Formulary 1982 - guide to the prescribing of medicines:
introduction; 30. A clinician's view on the team approach to drug
selection; 31. A pharmacists view on the team approach to drug selection;
32. Conclusion; 33. Restrictive formulary management with consequences for
the treatment of individual patients; 34. Changes in patterns of analgesic
use; Part X. Pharmacokinetics, Dialysis, I. V. Therapy: 35. Clinical
pharmacy improvement and interrelation with therapeutci team; 36. Clinical
pharmacist participation in a clinical trial - treatment of congestive
heart failure; 37. Metronidazole plasma levels after I. V. and rectal
administration; 38. Individual factors influencing aminoglycoside serum
levels; 39. Monitoring theophylline plasma levels; 40. Comparison of four
pharmacokinetic methods for individualizing phenytoin dosage; 41. Use of a
calculator program for individualized estimation of pheyoin kinetic
parameters by a least-squares technique; 42. On the importance of regular
Al determination in patients on regular hemodialysis (RHD); 43. Manufacture
of dialysis concentrate at the level of a hospital; 44. Hospital
preparation of injectable drugs by means of a multi-additive pump; 45. How
to detect physico-chemical incompatabilities in I. V. admixtures; 46.
Preparation of an enema containing metaminosalicylic acid
Concept of the Theraputic Team: 2. The concept of the therapeutic team; 3.
The view of a pharmacist; 4. The view of a physician; 5. The view of a
nurse; 6. The view of the clinical pharmacologist; 7. The view of an
academic; Part III. Practice of the Therapeutic Team: Parenteral Nutrition:
8. Parenteral nutrition - the team approach in a general hospital; 9.
Long-term follow-up in total parenteral nutrition; 10. Total parenteral
nutrition of children at the State University Hospital of Copenhagen; 11.
Compatibility of two different fat emulsions with amino-acids, carbohydrate
and electrolytes in parenteral nutrition mixtures; 12. Esophagus cancer and
parenteral nutrition: postoperative complications and P. N. I.
relationship. Preliminary study; Part IV. Oncology: 13. Central nervous
system prohylaxis of acute lymphoblastic leukemia with methotrexate; 14.
The treatment protocols of acute lymphoblastic leukemia in children; 15.
Guidelines for the safe handling of minibags; 16. Centralization of
preparation of cytotoxic drugs in the central pharmacy: one year of
experience; 17. Progress in the management of high dose methotrexate; 18.
Parmacokinetics of cytosine arabinoside in leukemic patients with normal
and impaired hepatic functions, preliminary results; PartV. Dermatology:
19. The operation of a therapeutic team in dermatology; Part VI. Epilepsy:
20. Team treatment of epilepsy; 21. Practices of the therapeutic team in
epilepsy; 22. Interdisciplinary approach to the treatment of epilepsy; 23.
The role of clinical pharmacist in the monitoring of antiepileptic therapy
in clinics with ambulant patients, our experience with 45 patients; Part
VII. Internal Medicine - Rheumatology: 24. An approach to the therapeutic
strategy in rheumatoid arthritis. Adverse reactions to penicillamine-like
drugs used in the treatment of rheumatoid arthritis; Part VIII. Nuclear
Medicine: 25. The nuclear medicine team; 26. Practice of the nuclear
medicine therapeutic team: the role of the physician; 27. Practice of the
nuclear medicine therapeutic team: the role of the physicist; 28. Practice
of the nuclear medicine therapeutic team: the role of the radiotherapist;
Part IX. Drug Selection: 29. Collaboration in drug selection - preparing
the London Hospital Formulary 1982 - guide to the prescribing of medicines:
introduction; 30. A clinician's view on the team approach to drug
selection; 31. A pharmacists view on the team approach to drug selection;
32. Conclusion; 33. Restrictive formulary management with consequences for
the treatment of individual patients; 34. Changes in patterns of analgesic
use; Part X. Pharmacokinetics, Dialysis, I. V. Therapy: 35. Clinical
pharmacy improvement and interrelation with therapeutci team; 36. Clinical
pharmacist participation in a clinical trial - treatment of congestive
heart failure; 37. Metronidazole plasma levels after I. V. and rectal
administration; 38. Individual factors influencing aminoglycoside serum
levels; 39. Monitoring theophylline plasma levels; 40. Comparison of four
pharmacokinetic methods for individualizing phenytoin dosage; 41. Use of a
calculator program for individualized estimation of pheyoin kinetic
parameters by a least-squares technique; 42. On the importance of regular
Al determination in patients on regular hemodialysis (RHD); 43. Manufacture
of dialysis concentrate at the level of a hospital; 44. Hospital
preparation of injectable drugs by means of a multi-additive pump; 45. How
to detect physico-chemical incompatabilities in I. V. admixtures; 46.
Preparation of an enema containing metaminosalicylic acid